**Name of journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 50052

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Risk of inflammatory bowel disease in patients with chronic obstructive pulmonary disease: A nationwide, population-based study**

Lee J *et al*. Risk of IBD in COPD patients

Jooyoung Lee, Jong Pil Im, Kyungdo Han, Seona Park, Hosim Soh, Kukhwan Choi, Jihye Kim, Jaeyoung Chun, Joo Sung Kim

**Jooyoung Lee, Joo Sung Kim,** Department of Internal Medicine and Healthcare Research Institute, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul 06236, South Korea

**Jooyoung Lee, Jong Pil Im, Seona Park, Hosim Soh, Kukhwan Choi, Joo Sung Kim,** Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul 03080, South Korea

**Kyungdo Han,** Department of Biostatics, College of Medicine, Catholic University of Korea, Seoul 06591, South Korea

**Jihye Kim,** Department of Internal Medicine, CHA Gangnam Medical Center, CHA University, Seoul 06135, South Korea

**Jaeyoung Chun,** Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, South Korea

**ORCHID number:** Jooyoung Lee (0000-0003-1652-088X); Jong Pil Im (0000-0003-1584-0160); Kyungdo Han (0000-0002-6096-1263); Seona Park (0000-0002-7281-0833); Hosim Soh (0000-0001-5107-6521); Kukhwan Choi (0000-0001-5083-1831); Jihye Kim (0000-0003-0763-2935); Jaeyoung Chun (0000-0002-4212-0380); Joo Sung Kim (0000-0001-6835-4735).

**Author contributions:** Lee J, Han KD and Im JP design the research; Han KD, Park S, Soh H, and Choi K contributed in data acquisition; Lee J and Han KD contributed in data analysis and interpretation; Lee J and Im JP drafted the manuscript; Kim J, Chun J and Kim JS critically revised the manuscript; All authors approved the final manuscript.

**Institutional Review Board statement:** The study protocol was approved by the Seoul National University Hospital Institutional Review Board (H-1703-107-840).

**Informed consent statement:** All personal information was encrypted and all data were anonymous. And informed consent was waived by the Seoul National University Hospital Institutional Review Board because of retrospective study design.

**Conflict-of-interest statement:** All authors declare no conflicts-of-interest related to this article.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Corresponding author: Jong Pil Im, MD, PhD, Professor, Doctor,** Department of Internal Medicine and Liver Research Instititute, Seoul National University College of Medicine, 101 Daehak-ro, Chongno-gu, Seoul 03080, South Korea. [jpim0911@snu.ac.kr](mailto:jpim0911@snu.ac.kr)

**Telephone:** +82-2-20720638

**Received:** July 2, 2019

**Peer-review started:** July 2, 2019

**First decision:** August 2, 2019

**Revised:** September 18, 2019

**Accepted:** October 17, 2019

**Article in press:** October 17, 2019

**Published online:** November 14,2019

**Abstract**

***BACKGROUND***

There is a growing evidence regarding an increased risk of inflammatory bowel disease (IBD) among patients with airway diseases.

***AIM***

To investigate the influence of chronic obstructive pulmonary disease (COPD) on the risk of IBD.

***METHODS***

A nationwide, population-based study was conducted using data from the National Health Insurance Service database. A total of 1303021 patients with COPD and 6515105 non-COPD controls were identified. The COPD group was divided into the severe and the mild COPD group according to diagnostic criteria. The risk of IBD in patients with COPD compared to controls was analyzed by Cox proportional hazard regression models. The cumulative incidences of IBD were compared between the groups.

***RESULTS***

The COPD group had higher incidences of IBD compared to non-COPD controls (incidence rate, 9.98 *vs* 7.18 per 100000 person-years, *P* < 0.001). The risk of IBD in the COPD group was increased by 1.38 (adjusted hazard ratio (HR); 95%CI: 1.25-1.52). The incidence rate of IBD was higher in the severe COPD group than in the mild COPD group (12.39 *vs* 9.77 per 100000 person-year, *P* < 0.001). The severity of COPD was associated with an increased risk of IBD (adjusted HR 1.70 in severe COPD, 95%CI: 1.27-2.21 and adjusted HR 1.35 in mild COPD, 95%CI: 1.22-1.49)

***CONCLUSION***

The incidences of IBD were significantly increased in COPD patients in South Korea and the risk of developing IBD also increased as the severity of COPD increased.

**Key words:** Claim data; Inflammatory bowel disease; Chronic obstructive pulmonary disease; Crohn’s disease; Ulcerative colitis

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** In this nationwide population-based study, we showed that the incidence of inflammatory bowel disease (IBD) was higher in chronic obstructive pulmonary disease (COPD) patients compared to age-and sex-matched controls without IBD in South Korea. And the risk of developing IBD also increased as the severity of COPD increased. It is important to be aware of the gastrointestinal symptoms indicative of IBD in COPD patients. Accurate clinical assessment should be done, especially in patients with severe COPD in order to prevent complications and avoid excess medical expenses.

Lee J, Im JP, Han K, Park S, Soh H, Choi K, Kim J, Chun J, Kim JS. Risk of inflammatory bowel disease in patients with chronic obstructive pulmonary disease: A nationwide, population-based study. *World J Gastroenterol* 2019; 25(42): 6354-6364

**URL:** https://www.wjgnet.com/1007-9327/full/v25/i42/6354.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v25.i42. 6354

**INTRODUCTION**

Inflammatory bowel disease (IBD), which is divided into Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic idiopathic disorder causing inflammation of the gastrointestinal tract. However, IBD should be regarded as a systemic disorder not limited to the gastrointestinal tract because extraintestinal manifestations of IBD are frequent and may occur before or after IBD diagnosis[1]. Extraintestinal manifestation frequently affect joints, skin, hepatobiliary tract and eye. Although the lung is less affected than other organ, IBD is known to be associated with a variety of lung disease and airway disease is the most common respiratory manifestation in IBD patients[2-5].

Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow limitation, which is caused by chronic airway inflammation and lung parenchymal destruction. It is well-known that not only respiratory symptoms but also extra-pulmonary manifestations such as cardiovascular compromise, dysfunction of skeletal muscles, osteoporosis, and anemia can result in impaired functional capacity and increased mortality in COPD patients. The gastrointestinal manifestations are no exception to this, and a recent report showed that complaints of gastrointestinal symptoms may be higher in patients with COPD than in healthy individuals[6]. Furthermore, the associations of COPD with specific gastrointestinal disease were investigated. And there is a growing evidence regarding an increased risk of IBD incidence among patients with airway diseases including COPD[7-10].

South Korea has a considerably higher prevalence of COPD than other countries, with 15.5/1000 people diagnosed with COPD annually[11,12]. Meanwhile, the incidence of IBD in South Korea has increased approximately 10-fold over the last two decades, which has led to South Korea having one of the highest incidence of IBD among Asian countries[13-16]. These trends of incidence and prevalence may lead to considerable economic burdens and challenge for the healthcare system. Asian IBD is known to be different from that of the Western countries in s pathophysiology, clinical manifestation and response to treatment[17-19].

Thus, in the present study, we aimed to investigate the association between COPD and IBD represented by CD and UC using the large data in Asia. We also aimed to study the influence of COPD on the risk of IBD according to the severity of COPD. Consideration of this association may maximize the efficacy of prevention and treatment approaches to these chronic disease.

**MATERIALS AND METHODS**

***Data source***

This nationwide, population-based study was conducted using data from the National Health Insurance Service (NHIS) database. The South Korean government administers the NHIS as a mandatory health insurance system covering approximately 97% of the South Korean population; the remaining 3% represent the lower income population covered by the Medical Aid program. The NHIS database provides comprehensive information about demographics, medical treatments, procedures, outpatient and inpatient care, and disease diagnoses according to the International Classification of Disease, 10th revision (ICD-10). In addition, in 2007, the NHIS established a registration program for rare intractable disease (RID), which included IBD, to provide enhanced reimbursement for medical costs that were associated with rare diseases (affecting < 20000 people in Korea). To qualify for enrolment in the RID program, patients require a diagnosis from a certified physicians and approval by the NHIS.

***Study population and patient identification***

We identified COPD patients based on the following diagnostic criterion: Conditions for which an individual should visit the medical facility at least twice per year with both a COPD diagnostic code and a prescription for one or more COPD medications between January 2010 and December 2014. Similar to previous studies[20-22], the detailed diagnostic criteria of COPD are as follows: > 40 years of age; ICD-10 codes for COPD (J43-J44, except J430); and use of more than one drug for COPD such as a long-acting muscarinic antagonist (LAMA), long-acting beta-2 agonist (LABA), inhaled corticosteroid (ICS), ICS plus LABA, short-acting muscarinic antagonist (SAMA), short-acting beta-2 agonist (SABA), SAMA plus SABA, methylxanthines, systemic corticosteroids, and systemic beta agonists. Patients with COPD were divided into the mild COPD group and severe COPD group and severe COPD was defined according to the following severity criteria: (1) Tertiary hospital care patient who met the definition of COPD described above; (2) Use of triple inhaler therapy at least once per year (ICS+LABA+LAMA). In addition, patients in the COPD group were subsequently 1:5 matched with individuals without COPD (non-COPD controls) for age and sex.

Incident cases of IBD were defined when the patients in the COPD group and non-COPD controls met the case definition for CD or UC during January 2010 and December 2014 and had been free of IBD diagnosis for at least 2 years prior to the beginning of the COPD case-defining period. We identified IBD patients using codes from the ICD-10 and the RID registration system (V code). Cases that involved CD were identified if they had both ICD-10 code K50 and V code V130, while cases that involved UC were identified if they had both ICD-10 code K51 and V code V131. Since IBD-unclassified is not registered in NHIS database and RID system as a definite diagnostic code, it was excluded from the analysis. We defined the time point at which this diagnosis was claimed using ICD-10 code and V code as “time 0” and identified IBD patients.

For inclusion in the present study, patients had to fulfill the diagnostic criteria for IBD, which were based on the clinical features, endoscopic findings, and histologic findings that are required for registration in the RID program. Previous studies have validated the accuracy of the RID database for both UC and CD diagnoses[14, 23, 24].

***Statistical analysis***

Statistical analyses were performed with the R program, version 3.4.3 (The R Foundation for Statistical Computing, Vienna, Austria, <http://www.R-project.org>) and SAS, version 9.2 (SAS Institute Inc., Cary, NC, United States) for Windows. Random selection of age- and sex-matched controls was performed using the SAS algorithm. Data for continuous variables are presented as the mean and standard deviation[25]. Data for categorical variables are presented as the numbers and percentages. Differences in baseline characteristics and comorbidities between the COPD group and non-COPD controls were analyzed with independent t-tests and *χ*2 tests, as appropriate*.* Incidence rates of IBD were calculated by dividing the number of events by 1000000 person-years of follow-up for each group. Cox proportional hazard regression models considering time-varying covariates were used to calculate the hazard ratio (HR) and 95% confidence interval (CI) for the risk of IBD in patients with COPD compared to controls[26]. The cumulative incidences of IBD were compared between the groups with the Kaplan-Meier method and the log-rank test. A *P* value < 0.05 was considered statistically significant.

***Ethical consideration***

All data were obtained without identifiable information, such as the registration number, patient’s name, or medical institution. This study’s protocol was approved by the institutional review board of Seoul National University Hospital (H-1703-107-840). All data base was encrypted and anonymous; we did not obtain informed consent from the study population.

**RESULTS**

***Baseline characteristics of study population***

A total of 1303021 patients with COPD and 6515105 non-COPD controls were included in this study. The mean age of the study population was 57.1 ± 10.7 years and the mean duration of follow-up was 3.9 ± 1.4 years. The number of patients with severe COPD was 111459, representing 8.6% of all COPD patients and 1191562 patients (91.4%) had mild COPD. (Table 1) Compared to non-COPD controls, the COPD group had lower proportions of urban. However, the COPD group had significantly higher proportions of individuals with the lower 20% incomes than non-COPD controls. In the case of comorbidity, the COPD group had a higher prevalence of diabetes mellitus, hypertension, and dyslipidemia.

***Development of IBD in patients with chronic obstructive pulmonary disease***

Comparison of the incidence rate and risk of IBD between patients with chronic obstructive pulmonary disease and con-COPD controls is presented in Table 2. In the COPD group, 513 patients (0.04%) developed IBD in the follow-up period, whereas 1,846 non-COPD controls (0.03%) developed IBD. The COPD group had higher incidences of total IBD compared to non-COPD controls (Figure 1). The risk of IBD in the COPD group was increased by 1.38 (adjusted HR; 95%CI: 1.25-1.52). Among the 513 patents with IBD in the COPD group, 406 were diagnosed with UC and 107 with CD. The incidence rate of UC was higher in the COPD group than in the non-COPD controls. CD also developed more frequently in the COPD group than in non-COPD controls. There was an increased risk of developing both UC and CD in the COPD group compared to in non-COPD controls.

***Incidence rates and relative risks of IBD according to chronic obstructive pulmonary disease severity***

Table 3 reports the number of events, calculated incidence rates, and unadjusted and adjusted HRs for IBD in the COPD group according to COPD severity. The incidence rate of overall IBD was higher in the severe COPD group than in the mild COPD group) (Figure 2). Both UC and CD were developed more frequently in the severe COPD group than in the mild COPD group. The severity of COPD was associated with an increased risk of developing IBD. When IBD is classified as UC and CD separately, patients with severe COPD also had increased risk of developing UC and CD compared to not only non-COPD controls but also the mild COPD group. This tendency of increased risk of IBD according to the severity of COPD was more prominent in CD than in UC

***Subgroup analysis according to sex and age***

For the subgroup analysis, of the entire study population was dichotomized according to sex and age. The risk of IBD in the COPD group compared to the non-COPD controls was analyzed according to sex and age (Table 4). Male patients with COPD had increased risks of developing CD and UC compared to male patients without COPD. This result was same for female patients with COPD. When the risk of developing IBD was analyzed according to age, the risk of developing IBD in the COPD group was higher than that in the non-COPD controls at all ages. In addition, the risk of IBD increased with the severity of COPD irrespective of sex and age, and this tendency was more prominent in CD than in UC.

**DISCUSSION**

This is a large-scale and nationwide study to assess the risk IBD in COPD patients compared to non-COPD controls. Several studies of regions with high incidence of IBD such as Europe and Canada have reported similar findings[7-9]; however, this is the first study conducted in Asia with a previously low prevalence of IBD. In addition, to our best knowledge, this is the first study that revealed a close association between the severity of COPD and the risk of developing IBD.

We found that the incidence of IBD (UC and CD) in COPD patients was higher compared to that in non-COPD controls. The higher risk of IBD in COPD patients might be explained by the genetics, pathological background, and environmental factors shared by these two disease. There are several reports investigating genes that contribute to the development of both IBD and COPD. NOD2 is a cellular protein that recognizes the bacterial muramyl dipeptide as a major component of the bacterial cell wall. NOD2 mutations were significantly identified in patients with CD, and recent studies have also reported this mutation in COPD patients[27].

The Hedgehog-interacting protein gene that is shown to be a potential susceptibility locus for COPD is also important in the development of the intestinal crypt axis and further studies are required to identify whether this gene contributes to the disease overlap between COPD and IBD[28]. Dysregulation of protease activity also has a role in both COPD and IBD. Increased levels of epithelial and leukocyte matrix metalloproteinases, which have a role in the digestion of key components in mucosal structural integrity have been associated with the pathogenesis of COPD and IBD[29-33].

Development of IBD in patients with COPD can also be explained by the hypothesis that systemic inflammation is caused by overspill of multiple inflammatory mediators including C-reactive protein, IL-6, fibrinogen and activated leucocytes resulting from lung inflammation[34]. Especially, several studies revealed that plasma tumor necrosis factor (TNF-α) and its soluble receptor are increased in patients with COPD than in healthy controls[35-37]. TNF-α is a pivotal cytokine in IBD pathogenesis and IBD can be assumed to be one of the systemic inflammation caused by COPD. However, despite this evidence and hypothesis, treatment with TNF-α inhibitors have not shown significant benefit in patients with COPD[38]. This may suggest that COPD is a highly complex inflammatory disease in which many other cytokines and mediators are involved, and blocking a single cytokine does not necessarily lead to a clinically significant effect[39].

In addition, microbiomes common to the lung and gastrointestinal tract, as well as autoimmune components of both diseases, can support the link between the two diseases. We also demonstrated that the risk of developing UC and CD in COPD patients also increased with the severity of COPD and this tendency was more pronounced in CD than in UC. This can be explained by understanding the effect of hypoxia on IBD pathogenesis. The intestinal mucosal barrier is made up of epithelial apical junction complexes, consisting of tight junctions and adherence junctions, which are sensitive to hypoxia. Severe hypoxemia caused by COPD is thought to evoke diminished splanchnic perfusion and result in inadequate oxygen delivery to the intestinal mucosal, causing tissue hypoxia, which is associated with increased enterocyte damage and integrity loss[40, 41]. In addition, mucosal barrier loss can be accelerated by inflammatory mediators, which are known to circulate during COPD aggravation as above mentioned[42]. For instance, cytokines can lead to alterations in the structure of tight junctions, thereby resulting in enhanced para-cellular permeability and barrier loss[43]. The effects of hypoxia are expected to be more severe as the severity of COPD increases, and a recent study showed an increased intestinal permeability in patients undergoing acute exacerbations of COPD compared to the same patients in a stable condition of COPD[44].

In this study, the number of IBD patients with UC was higher than those with CD in the COPD group. This can be assumed to be due to the higher incidence of UC in the entire IBD population in Korea compared to that of CD[16]. In addition, it may be because of the nature of the disease that older patients are more likely to be present in the COPD group. Approximately 10%-15% of IBD is diagnosed after the age of 60 and older-onset UC is more common than CD[45-47].

Smoking is the most important risk factor for COPD, also affecting the pathogenesis of IBD, protecting against UC, and promoting the development of CD[48, 49]. Nevertheless, our study could not make adjustment for the smoking status due to lack of information, and this is a weakness of this study. However, an analysis of the database including the smoking status of the Korean population from the national health screening program provided by the NHIS revealed that the proportion of ex- and current smokers was significantly higher in the COPD group than in non-COPD controls. (33.3% *vs* 31.1%, *P* < 0.001). And the proportion of IBD patients was also higher in the COPD group than in non-COPD controls (0.04% *vs* 0.03%, *P* < 0.001) (Supplementary material).

Our study could not reflect the actual clinical situation, and this is one of the weaknesses using administrative data. This limitation is associated with the possibility of overlooking the risk variables that are important for disease development. A well-designed prospective observational cohort study that combine administrative data and actual clinical data including medications and other clinical covariates is needed to reveal more precisely the association between COPD and IBD.

In conclusion, the incidences of both CD and UC were significantly increased in COPD patients in South Korea and the risk of developing IBD also increased as the severity of COPD increased. It is important to be aware of the gastrointestinal symptoms indicative of IBD in COPD patients. Accurate clinical assessment should be done, especially in patients with severe COPD in order to prevent complications and avoid excess medical expenses.

**ARTICLE HIGHLIGHTS**

***Research background***

Inflammatory bowel disease (IBD) is known to be associated with airway disease and there is a growing evidence of increased risk of IBD among patients with chronic obstructive pulmonary disease (COPD).

***Research motivation***

South Korea has a considerably high prevalence of COPD and is one of the highest incidence of IBD among Asian countries. Previous western studies have reported the risk of IBD in COPD patients, however, no research based on Asian data has been reported.

***Research objectives***

To estimate the incidence of IBD in patients with COPD compared to non-COPD controls and the risk of IBD development according to COPD severity.

***Research methods***

From January 2010 and December 2014, patients with COPD were identified using International Classification of Disease, 10th revision (ICD-10 code) and prescription records from the National Health Insurance (NHI) database. The COPD patients were divided into the severe and the mild COPD group. And these patients were subsequently 1:5 matches with individuals without COPD. Newly diagnosed IBD patients with Crohn’s disease and ulcerative colitis were identified using ICD-10 code and the rare intractable disease registration program codes from NHI database. The risk of IBD in COPD patients compared to controls was analyzed by Cox proportional hazard regression models. The cumulative incidence of IBD were compared between the groups.

***Research results***

The COPD group had higher incidences of IBD compared to non-COPD controls and the risk of IBD in the COPD group was increased. The incidence rate of IBD was higher in the severe COPD group than in the mild COPD group.

***Research conclusions***

The incidences of IBD were significantly increased in COPD patients in South Korea and the risk of developing IBD also increased as the severity of COPD increased.

***Research perspectives***

Careful monitoring the gastrointestinal symptoms indicative of IBD in COPD patients is important. Accurate clinical assessment should be done, especially in patients with severe COPD in order to determine the best strategies to prevent complications.

**REFERENCES**

1 **Vavricka SR**, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal Manifestations of Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2015; **21**: 1982-1992 [PMID: 26154136 DOI: 10.1097/MIB.0000000000000392]

2 **Bernstein CN**, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. *Gastroenterology* 2005; **129**: 827-836 [PMID: 16143122 DOI: 10.1053/j.gastro.2005.06.021]

3 **Black H**, Mendoza M, Murin S. Thoracic manifestations of inflammatory bowel disease. *Chest* 2007; **131**: 524-532 [PMID: 17296657 DOI: 10.1378/chest.06-1074]

4 **Yilmaz A**, Yilmaz Demirci N, Hoşgün D, Uner E, Erdoğan Y, Gökçek A, Cağlar A. Pulmonary involvement in inflammatory bowel disease. *World J Gastroenterol* 2010; **16**: 4952-4957 [PMID: 20954282 DOI: 10.3748/wjg.v16.i39.4952]

5 **Betancourt SL**, Palacio D, Jimenez CA, Martinez S, Marom EM. Thoracic manifestations of inflammatory bowel disease. *AJR Am J Roentgenol* 2011; **197**: W452-W456 [PMID: 21862772 DOI: 10.2214/AJR.10.5353]

6 **Tielemans MM**, Jaspers Focks J, van Rossum LG, Eikendal T, Jansen JB, Laheij RJ, van Oijen MG. Gastrointestinal symptoms are still prevalent and negatively impact health-related quality of life: a large cross-sectional population based study in The Netherlands. *PLoS One* 2013; **8**: e69876 [PMID: 23922836 DOI: 10.1371/journal.pone.0069876]

7 **Raj AA**, Birring SS, Green R, Grant A, de Caestecker J, Pavord ID. Prevalence of inflammatory bowel disease in patients with airways disease. *Respir Med* 2008; **102**: 780-785 [PMID: 18321696 DOI: 10.1016/j.rmed.2007.08.014]

8 **Ekbom A**, Brandt L, Granath F, Löfdahl CG, Egesten A. Increased risk of both ulcerative colitis and Crohn's disease in a population suffering from COPD. *Lung* 2008; **186**: 167-172 [PMID: 18330638 DOI: 10.1007/s00408-008-9080-z]

9 **Brassard P**, Vutcovici M, Ernst P, Patenaude V, Sewitch M, Suissa S, Bitton A. Increased incidence of inflammatory bowel disease in Québec residents with airway diseases. *Eur Respir J* 2015; **45**: 962-968 [PMID: 25406447 DOI: 10.1183/09031936.00079414]

10 **Vutcovici M**, Brassard P, Bitton A. Inflammatory bowel disease and airway diseases. *World J Gastroenterol* 2016; **22**: 7735-7741 [PMID: 27678355 DOI: 10.3748/wjg.v22.i34.7735]

11 **Rhee CK**. High prevalence of chronic obstructive pulmonary disease in Korea. *Korean J Intern Med* 2016; **31**: 651-652 [PMID: 27378127 DOI: 10.3904/kjim.2016.196]

12 **Leem AY**, Park B, Kim YS, Jung JY, Won S. Incidence and risk of chronic obstructive pulmonary disease in a Korean community-based cohort. *Int J Chron Obstruct Pulmon Dis* 2018; **13**: 509-517 [PMID: 29440888 DOI: 10.2147/COPD.S148618]

13 **Yang SK**, Yun S, Kim JH, Park JY, Kim HY, Kim YH, Chang DK, Kim JS, Song IS, Park JB, Park ER, Kim KJ, Moon G, Yang SH. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. *Inflamm Bowel Dis* 2008; **14**: 542-549 [PMID: 17941073 DOI: 10.1002/ibd.20310]

14 **Kim HJ**, Hann HJ, Hong SN, Kim KH, Ahn IM, Song JY, Lee SH, Ahn HS. Incidence and natural course of inflammatory bowel disease in Korea, 2006-2012: a nationwide population-based study. *Inflamm Bowel Dis* 2015; **21**: 623-630 [PMID: 25647154 DOI: 10.1097/MIB.0000000000000313]

15 **Ng WK**, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. *Intest Res* 2016; **14**: 111-119 [PMID: 27175111 DOI: 10.5217/ir.2016.14.2.111]

16 **Jung YS**, Han M, Kim WH, Park S, Cheon JH. Incidence and Clinical Outcomes of Inflammatory Bowel Disease in South Korea, 2011-2014: A Nationwide Population-Based Study. *Dig Dis Sci* 2017; **62**: 2102-2112 [PMID: 28593437 DOI: 10.1007/s10620-017-4640-9]

17 **Ng SC**, Bernstein CN, Vatn MH, Lakatos PL, Loftus EV Jr, Tysk C, O'Morain C, Moum B, Colombel JF; Epidemiology and Natural History Task Force of the International Organization of Inflammatory Bowel Disease (IOIBD). Geographical variability and environmental risk factors in inflammatory bowel disease. *Gut* 2013; **62**: 630-649 [PMID: 23335431 DOI: 10.1136/gutjnl-2012-303661]

18 **Ng SC**. Epidemiology of inflammatory bowel disease: focus on Asia. *Best Pract Res Clin Gastroenterol* 2014; **28**: 363-372 [PMID: 24913377 DOI: 10.1016/j.bpg.2014.04.003]

19 **Ye BD**. Could early anti-tumor necrosis factor therapy change the prognosis of Crohn's disease? *Intest Res* 2014; **12**: 263-265 [PMID: 25374489 DOI: 10.5217/ir.2014.12.4.263]

20 **Kim J**, Lee JH, Kim Y, Kim K, Oh YM, Yoo KH, Rhee CK, Yoon HK, Kim YS, Park YB, Lee SW, Lee SD. Association between chronic obstructive pulmonary disease and gastroesophageal reflux disease: a national cross-sectional cohort study. *BMC Pulm Med* 2013; **13**: 51 [PMID: 23927016 DOI: 10.1186/1471-2466-13-51]

21 **Kim J**, Rhee CK, Yoo KH, Kim YS, Lee SW, Park YB, Lee JH, Oh Y, Lee SD, Kim Y, Kim K, Yoon H. The health care burden of high grade chronic obstructive pulmonary disease in Korea: analysis of the Korean Health Insurance Review and Assessment Service data. *Int J Chron Obstruct Pulmon Dis* 2013; **8**: 561-568 [PMID: 24277985 DOI: 10.2147/COPD.S48577]

22 **Park SC**, Kim YS, Kang YA, Park EC, Shin CS, Kim DW, Rhee CK. Hemoglobin and mortality in patients with COPD: a nationwide population-based cohort study. *Int J Chron Obstruct Pulmon Dis* 2018; **13**: 1599-1605 [PMID: 29805259 DOI: 10.2147/COPD.S159249]

23 **Hong SN**, Kim HJ, Kim KH, Han SJ, Ahn IM, Ahn HS. Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea. *Aliment Pharmacol Ther* 2017; **45**: 253-263 [PMID: 27933686 DOI: 10.1111/apt.13851]

24 **Park S**, Chun J, Han KD, Soh H, Choi K, Kim JH, Lee J, Lee C, Im JP, Kim JS. Increased end-stage renal disease risk in patients with inflammatory bowel disease: A nationwide population-based study. *World J Gastroenterol* 2018; **24**: 4798-4808 [PMID: 30479466 DOI: 10.3748/wjg.v24.i42.4798]

25 **Zhang Z**. Univariate description and bivariate statistical inference: the first step delving into data. *Ann Transl Med* 2016; **4**: 91 [PMID: 27047950 DOI: 10.21037/atm.2016.02.11]

26 **Zhang Z**, Reinikainen J, Adeleke KA, Pieterse ME, Groothuis-Oudshoorn CGM. Time-varying covariates and coefficients in Cox regression models. *Ann Transl Med* 2018; **6**: 121 [PMID: 29955581 DOI: 10.21037/atm.2018.02.12]

27 **Kinose D,** Ogawa E, Hirota T, Ito I, Kudo M, Haruna A, Marumo S, Hoshino Y, Muro S, Hirai T, Sakai H, Date H, Tamari M, Mishima M. A NOD2 gene polymorphism is associated with the prevalence and severity of chronic obstructive pulmonary disease in a Japanese population. Respirology 2012; **17**: 164-171 [PMID: 21943069 DOI: 10.1111/j.1440-1843.2011.02069.x]

28 **Madison BB**, Braunstein K, Kuizon E, Portman K, Qiao XT, Gumucio DL. Epithelial hedgehog signals pattern the intestinal crypt-villus axis. *Development* 2005; **132**: 279-289 [PMID: 15590741 DOI: 10.1242/dev.01576]

29 **Vernooy JH**, Lindeman JH, Jacobs JA, Hanemaaijer R, Wouters EF. Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. *Chest* 2004; **126**: 1802-1810 [PMID: 15596677 DOI: 10.1378/chest.126.6.1802]

30 **Pender SL**, Li CK, Di Sabatino A, MacDonald TT, Buckley MG. Role of macrophage metalloelastase in gut inflammation. *Ann N Y Acad Sci* 2006; **1072**: 386-388 [PMID: 17057219 DOI: 10.1196/annals.1326.019]

31 **Vlahos R**, Bozinovski S, Jones JE, Powell J, Gras J, Lilja A, Hansen MJ, Gualano RC, Irving L, Anderson GP. Differential protease, innate immunity, and NF-kappaB induction profiles during lung inflammation induced by subchronic cigarette smoke exposure in mice. *Am J Physiol Lung Cell Mol Physiol* 2006; **290**: L931-L945 [PMID: 16361358 DOI: 10.1152/ajplung.00201.2005]

32 **Churg A**, Wang R, Wang X, Onnervik PO, Thim K, Wright JL. Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. *Thorax* 2007; **62**: 706-713 [PMID: 17311841 DOI: 10.1136/thx.2006.068353]

33 **Keely S**, Talley NJ, Hansbro PM. Pulmonary-intestinal cross-talk in mucosal inflammatory disease. *Mucosal Immunol* 2012; **5**: 7-18 [PMID: 22089028 DOI: 10.1038/mi.2011.55]

34 **Sinden NJ**, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of 'overspill' of inflammatory mediators from the lungs? Review of the evidence. *Thorax* 2010; **65**: 930-936 [PMID: 20627907 DOI: 10.1136/thx.2009.130260]

35 **Takabatake N**, Nakamura H, Abe S, Inoue S, Hino T, Saito H, Yuki H, Kato S, Tomoike H. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2000; **161**: 1179-1184 [PMID: 10764309 DOI: 10.1164/ajrccm.161.4.9903022]

36 **Broekhuizen R**, Grimble RF, Howell WM, Shale DJ, Creutzberg EC, Wouters EF, Schols AM. Pulmonary cachexia, systemic inflammatory profile, and the interleukin 1beta -511 single nucleotide polymorphism. *Am J Clin Nutr* 2005; **82**: 1059-1064 [PMID: 16280439 DOI: 10.1093/ajcn/82.5.1059]

37 **Di Francia M**, Barbier D, Mege JL, Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1994; **150**: 1453-1455 [PMID: 7952575 DOI: 10.1164/ajrccm.150.5.7952575]

38 **Matera MG**, Calzetta L, Cazzola M. TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. *Pulm Pharmacol Ther* 2010; **23**: 121-128 [PMID: 19853667 DOI: 10.1016/j.pupt.2009.10.007]

39 **Barnes PJ**. Unexpected failure of anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2007; **175**: 866-867 [PMID: 17446342 DOI: 10.1164/rccm.200702-253ED]

40 **Takala J**. Determinants of splanchnic blood flow. *Br J Anaesth* 1996; **77**: 50-58 [PMID: 8703630 DOI: 10.1093/bja/77.1.50]

41 **Grootjans J**, Lenaerts K, Derikx JP, Matthijsen RA, de Bruïne AP, van Bijnen AA, van Dam RM, Dejong CH, Buurman WA. Human intestinal ischemia-reperfusion-induced inflammation characterized: experiences from a new translational model. *Am J Pathol* 2010; **176**: 2283-2291 [PMID: 20348235 DOI: 10.2353/ajpath.2010.091069]

42 **Bathoorn E**, Kerstjens H, Postma D, Timens W, MacNee W. Airways inflammation and treatment during acute exacerbations of COPD. *Int J Chron Obstruct Pulmon Dis* 2008; **3**: 217-229 [PMID: 18686731]

43 **Turner JR**. Intestinal mucosal barrier function in health and disease. *Nat Rev Immunol* 2009; **9**: 799-809 [PMID: 19855405 DOI: 10.1038/nri2653]

44 **Sprooten RTM**, Lenaerts K, Braeken DCW, Grimbergen I, Rutten EP, Wouters EFM, Rohde GGU. Increased Small Intestinal Permeability during Severe Acute Exacerbations of COPD. *Respiration* 2018; **95**: 334-342 [PMID: 29393240 DOI: 10.1159/000485935]

45 **Ng SC**, Tang W, Ching JY, Wong M, Chow CM, Hui AJ, Wong TC, Leung VK, Tsang SW, Yu HH, Li MF, Ng KK, Kamm MA, Studd C, Bell S, Leong R, de Silva HJ, Kasturiratne A, Mufeena MNF, Ling KL, Ooi CJ, Tan PS, Ong D, Goh KL, Hilmi I, Pisespongsa P, Manatsathit S, Rerknimitr R, Aniwan S, Wang YF, Ouyang Q, Zeng Z, Zhu Z, Chen MH, Hu PJ, Wu K, Wang X, Simadibrata M, Abdullah M, Wu JC, Sung JJY, Chan FKL; Asia–Pacific Crohn's and Colitis Epidemiologic Study (ACCESS) Study Group. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. *Gastroenterology* 2013; **145**: 158-165.e2 [PMID: 23583432 DOI: 10.1053/j.gastro.2013.04.007]

46 **Charpentier C**, Salleron J, Savoye G, Fumery M, Merle V, Laberenne JE, Vasseur F, Dupas JL, Cortot A, Dauchet L, Peyrin-Biroulet L, Lerebours E, Colombel JF, Gower-Rousseau C. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. *Gut* 2014; **63**: 423-432 [PMID: 23408350 DOI: 10.1136/gutjnl-2012-303864]


47 **Taleban S**, Colombel JF, Mohler MJ, Fain MJ. Inflammatory bowel disease and the elderly: a review. *J Crohns Colitis* 2015; **9**: 507-515 [PMID: 25870198 DOI: 10.1093/ecco-jcc/jjv059]

48 **Birrenbach T**, Böcker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. *Inflamm Bowel Dis* 2004; **10**: 848-859 [PMID: 15626903 DOI: 10.1097/00054725-200411000-00019]


49 **Parkes GC**, Whelan K, Lindsay JO. Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect. *J Crohns Colitis* 2014; **8**: 717-725 [PMID: 24636140 DOI: 10.1016/j.crohns.2014.02.002]

**P-Reviewer:** Cheng DY, Can G, Jamali R, Madnani MA, Matowicka-Karna J, Serban ED, Tarnawski AS, Zhang ZH **S-Editor:** Wang J **L-Editor:** A **E-Editor:** Zhang YL

**Specialty type:** Gastroenterology and hepatology   
**Country of origin:** South Korea   
**Peer-review report classification**  
**Grade A (Excellent):** A  
**Grade B (Very good):** B, B, B  
**Grade C (Good):** C, C, C, C  
**Grade D (Fair):** 0 **Grade E (Poor):** 0



**Figure 1 The cumulative incidence of inflammatory bowel disease in chronic obstructive pulmonary disease group and non-chronic obstructive pulmonary disease controls.** IBD: Inflammatory bowel disease; COPD: Chronic obstructive pulmonary disease.



**Figure 2 Comparison of cumulative incidence of inflammatory bowel disease in patients with chronic obstructive pulmonary disease according to the severity of chronic obstructive pulmonary disease.** IBD: Inflammatory bowel disease; COPD: Chronic obstructive pulmonary disease.

**Table 1 Baseline characteristics of study population, *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Non-COPD controls (*n* = 6515105)** | **COPD group (*n* = 1303021)** | ***P* value** |
| Sex (Male %) | 2867470 (44.0) | 573494 (44.0) | 1 |
| Age (yr) | 57.1 ± 10.72 | 57.1 ± 10.72 | 1 |
| 40-64 | 5025580 (77.1) | 1005116 (77.1) |  |
| 65- | 1489525 (22.9) | 297905 (22.9) |  |
| COPD severity |  |  |  |
| Mild |  | 1191562 (91.4) |  |
| Severe |  | 111459 (8.6) |  |
| Income Low1 | 1597508 (24.5) | 357627 (27.5) | < 0.001 |
| Urban residents | 2965581 (45.8) | 567359 (44.1) |  |
| Comorbidity |  |  |  |
| Diabetes mellitus | 640544 (9.8) | 164860 (12.7) | < 0.001 |
| Hypertension | 1703988 (26.2) | 418880 (32.2) | < 0.001 |
| Dyslipidemia | 1002279 (15.4) | 272449 (20.9) | < 0.001 |
| Follow up duration (yr) | 3.9 ± 1.4 | 3.9 ± 1.4 | 0.8803 |

1Denotes subjects with annual income lower than 20% among total population. COPD: Chronic obstructive pulmonary disease.

**Table 2 Incidence rate and risk of inflammatory bowel disease in patients with chronic obstructive pulmonary disease**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Event** | **DURATION  (Person-years)** | **Incidence rate**  **of IBD** | **Model 11 HR (95%CI)** | **Model 22 HR (95%CI)** | ***P* value** |
|  |  | IBD | | | | | |
| COPD | No | 1846 | 25697723.08 | 7.18 | 1 (Ref.) | 1 (Ref.) | < 0.001 |
| Yes | 513 | 5139283.39 | 9.98 | 1.39 (1.26-1.53) | 1.379 (1.25-1.52) |
|  |  | UC | | | | | |
| COPD | No | 1540 | 25697723.08 | 5.99 | 1 (Ref.) | 1 (Ref.) | < 0.001 |
| Yes | 406 | 5139283.39 | 7.9 | 1.32 (1.18-1.47) | 1.315 (1.18-1.47) |
|  |  | CD | | | | | |
| COPD | No | 306 | 25697723.08 | 1.19 | 1 (Ref.) | 1 (Ref.) | < 0.001 |
| Yes | 107 | 5139283.39 | 2.08 | 1.75 (1.40-2.171) | 1.691 (1.35-2.10) |

1Model 1: adjustment for age and sex;

2Model 2: adjustment for model 1+ place of resident, income, diabetes mellitus, hypertension, dyslipidemia. CD: Crohn’s disease; CI: Confidence interval; COPD: Chronic obstructive pulmonary disease; HR: Hazard ratio; IBD: Inflammatory bowel disease; UC: Ulcerative colitis.

**Table 3 Incidence and risk of inflammatory bowel disease in patients with chronic obstructive pulmonary disease according to disease severity**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Event** | **DURATION  (Person-years)** | **Incidence rate**  **of IBD** | **Model 11 HR (95%CI)** | **Model 22 HR (95%CI)** | ***P* value** |
|  |  | IBD | | | | | |
| COPD Severity | Non | 1846 | 25697723.08 | 7.18 | 1 (Ref.) | 1 (Ref.) | < 0.001 |
| Mild | 461 | 4719752.21 | 9.77 | 1.36 (1.23-1.50) | 1.35 (1.22-1.49) |
| Severe | 52 | 419531.18 | 12.39 | 1.717 (1.29-2.24) | 1.70 (1.27-2.21) |
|  |  | UC | | | | | |
| COPD Severity | Non | 1540 | 25697723.08 | 5.99 | 1 (Ref.) | 1(Ref.) | < 0.001 |
| Mild | 371 | 4719752.21 | 7.86 | 1.31 (1.17-1.47) | 1.31 (1.17-1.47) |
| Severe | 35 | 419531.18 | 8.34 | 1.39 (0.97-1.91) | 1.38 (0.96-1.89) |
|  |  | CD | | | | | |
| COPD Severity | Non | 306 | 25697723.08 | 1.19 | 1 (Ref.) | 1(Ref.) | < 0.001 |
| Mild | 90 | 4719752.21 | 1.91 | 1.60 (1.26-2.02) | 1.548 (1.22-1.95) |
| Severe | 17 | 419531.18 | 4.05 | 3.38 (2.00-5.33) | 3.29 (1.94-5.20) |

1Model 1: adjustment for age and sex; 2Model 2: adjustment for model 1+ place of resident, income, diabetes mellitus, hypertension, dyslipidemia. CD: Crohn’s disease; CI: Confidence interval; COPD: Chronic obstructive pulmonary disease; HR: Hazard ratio; IBD: Inflammatory bowel disease; UC: Ulcerative colitis.

**Table 4 Risk of inflammatory bowel disease in patients with chronic obstructive pulmonary disease according to sex and age**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **COPD** | **IBD** | **UC** | **CD** |
| Male | No | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Yes | 1.47 (1.23-1.60) | 1.35 (1.16-1.55) | 1.75 (1.26-2.39) |
| Female | No | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Yes | 1.35 (1.16-1.55) | 1.27 (1.07-1.5) | 1.64 (1.20-2.21) |
| Age (40-64) | No | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Yes | 1.36 (1.21-1.52) | 1.31 (1.15-1.48) | 1.62 (1.25-2.08) |
| Age (65-) | No | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Yes | 1.46 (1.19-1.79) | 1.36 (1.07-1.71) | 1.93 (1.23-2.96) |

CD: Crohn’s disease; COPD: Chronic obstructive pulmonary disease; IBD: Inflammatory bowel disease; UC: Ulcerative colitis.